

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia, 30 November 2018: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) advises that the resolutions put to the Annual General Meeting of members today were carried.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, the following statistics are provided in respect of each resolution.

	Resolution	For	Against	Abstain	Discretionary
1	Adoption of Remuneration Report	22,300,948	475,010	893,560	6,890,095
2	Re-Election of Dr Irmgard Irminger-Finger	23,269,358	100,000	300,160	6,890,095
3	Approval of 10% Placement Capacity	20,331,712	3,117,808	211,998	6,890,095
4	Ratification of Placement under Listing Rule 7.1	18,992,685	3,157,808	1,511,025	6,890,095

All resolutions were carried on a show of hands.



Pauline Collinson
Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in early development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see www.bard1.com.